SMC approves Bavencio for bladder cancer
The treatment was not recommended by NICE for the NHS in England
Read More
Tag: Bavencio
Preliminary NICE ‘no’ for Merck’s Bavencio
The cost regulator has rejecting funding the drug as maintenance treatment of advanced/metastatic urothelial cancer
Read More
Bavencio, Imbruvica among latest SMC decisions
The committee accepted a number of drugs through the PACE process
Read More
UK bladder cancer patients get early access to Bavencio
UK MHRA has issued positive scientific opinion enabling the drug’s inclusion on the Early Access to Medicines Scheme
Read More
NICE green light for immunotherapy Bavencio
Merck and Pfizer’s drug will now be available on the NHS in combination with axitinib as a first-line treatment for kidney cancer
Read More
NICE backs Bavencio combo for kidney cancer
The combination of an immunotherapy with a targeted antiangiogenic therapy offers patients a novel treatment option
Read More
EMA to consider expanding use of Merck/Pfizer’s Bavencio
The regulator will assess its safety and efficacy as a treatment for bladder cancer
Read More
Merck’s Bavencio hits targets in bladder cancer interim analysis
Last year the drug disappointed in the Phase III JAVELIN Gastric 100 study, but has pulled itself back with new urothelial carcinoma data.
Read More
MHRA gives Bavencio, Inlyta combo Early Access to Medicines status
The opinion is for the indication of RCC, the most common kind of kidney cancer found in adults.
Read More
FDA approval for Bavencio combo in advanced RCC
The decision was based on positive results from the Phase III JAVELIN Renal 101 study.
Read More
Merck, Pfizer pull the plug on ovarian cancer trial
Merck and Pfizer are pulling the plug on a late-stage trial assessing the potential of their PD-L1 antibody avelumab in the front-line maintenance setting for ovarian cancer.
Read More
Bavencio combo gets FDA priority review for kidney cancer
The US Food and Drug Administration has accepted for priority review a supplemental Biologics License Application for Merck’s Bavencio (avelumab) in combination with Inlyta (axitinib) for patients with advanced renal cell carcinoma (RCC).
Read More
- MIT’s new MRI brain light-detecting technique could support brain cell studies
- PharmaTimes MSEA and NIEA awards are open for entry
- BBSRC invests £48m in Babraham Institute to advance lifelong health research
- NHS reduces long waits for cancer care and achieves faster ambulance responses
- MHRA’s AI Airlock to address challenges for regulating AI medical devices
